1. Survivin in autoimmune diseases
- Author
-
Minna Turkkila, Gergely Katona, Rille Pullerits, Malin C. Erlandsson, Karin M. E. Andersson, Maria-Jose Garcia-Bonete, S. Töyrä Silfverswärd, Mikael Brisslert, C. Wasen, Maria Bokarewa, and G. Gravina
- Subjects
0301 basic medicine ,Protein Conformation ,Survivin ,Immunology ,Context (language use) ,Biology ,Adaptive Immunity ,medicine.disease_cause ,Autoimmunity ,Autoimmune Diseases ,Inhibitor of Apoptosis Proteins ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,medicine ,Immunology and Allergy ,Animals ,Humans ,Hypoxia ,Inflammation ,Molecular pathology ,Smoking ,Autoantibody ,Acquired immune system ,medicine.disease ,Immunity, Innate ,Hematopoiesis ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cancer research ,Sunlight ,Oral lichen planus - Abstract
Survivin is a protein functionally important for cell division, apoptosis, and possibly, for micro-RNA biogenesis. It is an established marker of malignant cell transformation. In non-malignant conditions, the unique properties of survivin make it indispensable for homeostasis of the immune system. Indeed, it is required for the innate and adaptive immune responses, controlling differentiation and maintenance of CD4+ and CD8+ memory T-cells, and in B cell maturation. Recently, survivin has emerged as an important player in the pathogenesis of autoimmune diseases. Under the conditions of unreserved inflammation, survivin enhances antigen presentation, maintains persistence of autoreactive cells, and supports production of autoantibodies. In this context, survivin takes its place as a diagnostic and prognostic marker in rheumatoid arthritis, psoriasis, systemic sclerosis and pulmonary arterial hypertension, neuropathology and multiple sclerosis, inflammatory bowel diseases and oral lichen planus. In this review, we summarise the knowledge about non-malignant properties of survivin and focus on its engagement in cellular and molecular pathology of autoimmune diseases. The review highlights utility of survivin measures for clinical applications. It provides rational for the survivin inhibiting strategies and presents results of recent reports on survivin inhibition in modern therapies of cancers and autoimmune diseases.
- Published
- 2017